Advertisement

Search Results

Advertisement



Your search for The ASCO Post Staff matches 2774 pages

Showing 201 - 250


Douglas R. Lowy, MD, FAACR, Honored With 2021 AACR–Margaret Foti Award

The American Association for Cancer Research (AACR) presented Douglas R. Lowy, MD, FAACR, with the 2021 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the virtual AACR Annual Meeting 2021. Dr. Lowy is Chief of the Laboratory of Cellular Oncology,...

lung cancer
genomics/genetics

FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic EGFR Exon 20 Insertion–Mutated NSCLC

On May 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor and MET receptors, for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and...

AACR Announces Recipients of 2021 Scientific Achievement Awards and Lectureships

The American Association for Cancer Research (AACR) honored a number of cancer researchers, physician-scientists, advocates, and policymakers for their achievements during week 1 of the virtual AACR Annual Meeting 2021 (April 10–15, 2021). Several of these recipients were mentioned in previous...

AACR to Recognize the St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team With 2021 Team Science Award

The American Association for Cancer Research (AACR) will recognize the St. Baldrick’s Foundation–Stand Up To Cancer (SU2C) Pediatric Cancer Dream Team with the 2021 AACR Team Science Award. In early 2013, the St. Baldrick’s Foundation and SU2C collaborated to create a Pediatric Cancer Dream Team...

Lisa M. Coussens, PhD, FAACR, Elected AACR President-Elect for 2021–2022

The members of the American Association for Cancer Research (AACR) have elected Lisa M. Coussens, PhD, FAACR, as their President-Elect for 2021–2022. She started her official role as President-Elect on April 12, 2021, during the AACR’s Business Meeting of Members and will assume the Presidency in...

New President and Executive Council Officers for the Society of Surgical Oncology

The Society ofSurgical Oncology (SSO) recently announced its 2021–2022 elected Executive Council Officers, including its new President, Douglas S. Tyler, MD, MSHCT, FSSO. Dr. Tyler currently holds the John Woods Harris Distinguished Chair in Surgery at The University of Texas Medical Branch in...

lymphoma
lung cancer

FDA Pipeline: Applications Accepted for Marginal Zone Lymphoma and Lung Cancer

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to zanubrutinib in pretreated patients with marginal zone lymphoma, and accepted a biologics license application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line...

gastrointestinal cancer
genomics/genetics

Avapritinib vs Other Tyrosine Kinase Inhibitors for PDGFRA D842V–Mutated Gastrointestinal Stromal Tumors

Data from a study published by Margaret von Mehren, MD, and colleagues in BMC Cancer showed that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V...

issues in oncology

Equitable Cancer Care: Steps Toward Meaningful Change

As President-Elect of ASCO, you are asked to choose a theme for your presidency. This can be a daunting task, as the theme will not only shape the discourse of your presidency, but also, more importantly, that of the Society. The subject should be one that reflects the needs of the cancer community ...

gastroesophageal cancer
immunotherapy

FDA Approves Nivolumab for Resected Esophageal or Gastroesophageal Junction Cancer

On May 20, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. CheckMate 577 Efficacy was evaluated in CheckMate ...

issues in oncology

American Cancer Society Releases Report on Cancer Prevention and Screening

An American Cancer Society (ACS) review of cancer prevention and early detection measures for 2018 and 2019 in the United States shows mixed progress. Smoking prevalence during this time was at an historic low, partly because most people who ever smoked have quit. However, obesity rates remained...

colorectal cancer
genomics/genetics

Standard Multigene Testing Could Detect More Hereditary Cancer Syndromes in Patients With Colorectal Cancer

Up to 38.6% of people with colon cancer who have a hereditary cancer syndrome—including 6.3% of those with Lynch syndrome—could have their conditions remain undetected with current universal tumor-screening methods, and at least 7.1% of people with colorectal cancer have an identifiable inherited...

lung cancer
immunotherapy

Heather A. Wakelee, MD, on NSCLC: Atezolizumab vs Best Supportive Care After Chemotherapy

Heather A. Wakelee, MD, of Stanford University Medical Center, discusses the primary disease-free survival results of IMpower010, a phase III study that compared adjuvant atezolizumab vs best supportive care after adjuvant chemotherapy in patients with early-stage resected non–small cell lung...

issues in oncology
health-care policy
legislation

Jingxuan Zhao, MPH, on How Medicaid Expansion Affects Long-Term Cancer Survival

Jingxuan Zhao, MPH, of the American Cancer Society, discusses study findings that showed worse long-term survival among low-income patients with cancer who live in states that have not expanded Medicaid eligibility (Abstract 6512).

skin cancer
immunotherapy

First-Line Nivolumab/Relatlimab vs Nivolumab Alone for Advanced Melanoma

Treatment with the anti–PD-1 therapy nivolumab plus the LAG-3–blocking antibody relatlimab extended time to disease progression for patients with previously untreated, unresectable, or metastatic melanoma. Findings from the RELATIVITY-047 trial were presented by Evan J. Lipson, MD, and colleagues...

prostate cancer

Increased PSA Screening Linked to Lower Risk of Advanced Prostate Cancer at Diagnosis and Death From the Disease in Younger Black Patients

Younger Black men undergoing frequent prostate-specific antigen (PSA) screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study by Qiao et al presented at a presscast in advance of the 2021...

colorectal cancer

USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening

Prompted by a rise in cases of colorectal cancer in people younger than 50, the U.S. Preventive Services Task Force (USPSTF) has recommended that individuals at average risk for the disease begin screening exams at age 45 instead of the traditional age of 50. The guideline changes, published in...

breast cancer
survivorship

Risk of Second Cancer by Hormone Receptor Status Among Breast Cancer Survivors

A new study has found breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, published by Hyuna Sung, PhD, and colleagues in the journal Cancer, stated that compared to the general population in the United States, the risk of new...

issues in oncology
health-care policy
legislation

Report Shows Medicaid Expansion Alone Does Not Resolve Disparities in Cancer Care

In the United States, Black and Latinx individuals have higher cancer mortality rates than patients of other races. Under the Patient Protection and Affordable Care Act (ACA) in 2014, many states expanded Medicaid eligibility, promising significant gains in coverage for racial minorities. But it...

symptom management

TLR4 as a Possible Therapeutic Target to Mitigate Cisplatin-Induced Hearing Loss

A research team has identified a receptor in cells that could play a role in preventing permanent hearing loss in childhood cancer survivors treated with the drug cisplatin. The researchers believe that by inhibiting the receptor, they may be able to better control otoxicity, according to findings...

skin cancer
genomics/genetics

Mutational Profile of Acral Nevi May Differ From Acral Melanoma

Melanocytic nevi are nonmalignant growths that arise from pigment-producing cells of the skin. They are mostly found in sun-exposed areas; however, they also can be found in sun-protected areas, such as the palms, soles of the feet, and nail beds, where they are known as acral nevi. While the...

breast cancer

Abemaciclib-Associated Adverse Events: Safety Analysis of monarchE

Treatment with abemaciclib, an orally available inhibitor of CDK4/6, has been associated with venous thromboembolic events (VTE), elevated aminotransferases (EAT), and interstitial lung disease (ILD). Although more episodes of VTE, EAT, and ILD were reported in patients receiving abemaciclib plus...

breast cancer

Long-Term Follow-up of Premenopausal Patients With Estrogen Receptor–Positive Breast Cancer: Goserelin and Tamoxifen

A 20-year follow-up of premenopausal patients with estrogen receptor–positive breast cancer and stratification by the molecular 70-gene risk signature suggested that patients at high risk of distant disease recurrence derive significant benefit from goserelin, while patients at low risk have...

breast cancer
gynecologic cancers
pancreatic cancer
genomics/genetics

ACMG Clinical Practice Resource Provides New Guidance for Management of Individuals With PALB2 Gene Variants

The American College of Medical Genetics and Genomics (ACMG) has released a clinical practice resource from a global team of specialists in cancer genetics that will help inform the clinical management of patients who harbor a PALB2 variant and may be at increased risk of developing breast,...

breast cancer
immunotherapy
symptom management

Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer

Drug-related interstitial lung disease occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan-nxki (T-DXd) at the approved dose of 5.4 mg/kg. In addition, the majority of these cases were classified as grade 1 or 2,...

breast cancer
immunotherapy

Atezolizumab/Carboplatin as Immune Induction in Patients With Metastatic Invasive Lobular Breast Cancer

First results from the phase II GELATO study evaluating atezolizumab plus carboplatin presented at the ESMO Breast Cancer Virtual Congress 2021 demonstrated clinical benefit in patients with metastatic invasive lobular breast cancer, particularly in patients with triple-negative invasive lobular...

kidney cancer
gynecologic cancers
hepatobiliary cancer
immunotherapy

FDA Pipeline: Priority Reviews in Kidney and Endometrial Cancers, Cholangiocarcinoma

Recently, the U.S. Food and Drug Administration (FDA) has granted Priority Review to the combination of pembrolizumab and lenvatinib for the treatment of both advanced renal cell carcinoma (RCC) and endometrial carcinoma. The FDA also granted Priority Review to ivosidenib for the treatment of...

breast cancer

Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics

The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors. This research was presented by...

lung cancer

Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated

PRESERVE 4 (ClinicalTrials.gov identifier: NCT04863248)—a multicenter, randomized, double-blind, placebo-controlled phase II study of trilaciclib administered prior to docetaxel in patients with metastatic non–small cell lung cancer (NSCLC) in the second- and third-line setting who have previously...

covid-19

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents

On May 10, the U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents aged 12 through 15. The FDA...

UPMC Hillman Names New Hematology Oncology Chief

Taofeek K. Owonikoko, MD, PhD, will join the University of Pittsburgh Medical Center (UMPC) Hillman Cancer Center and Department of Medicine as Chief of the Division of Hematology/Oncology. A physician-scientist board-certified in medical oncology, hematology, and internal medicine, Dr. Owonikoko...

Randall F. Holcombe, MD, MBA, Named Director of UVM Cancer Center and Chief of Hematology and Oncology

The Robert Larner, MD, College of Medicine at The University of Vermont (UVM), in collaboration with the UVM Health Network and the UVM Medical Center, has announced that Randall F. Holcombe, MD, MBA, has been appointed Director of the UVM Cancer Center and Chief of the Division of Hematology and...

covid-19

Surge of Patients With Advanced Cancer Expected Due to Delayed Diagnosis and Treatment During Pandemic

Pent up demand for cancer screenings, diagnostic workups, and treatments delayed or curtailed since the start of the pandemic is expected to result in a surge of patients—some with more advanced disease as a result of delays—seeking appointments with oncologists. “We are starting to see the...

Lombardi Comprehensive Cancer Center, Georgetown University Names Kieron Dunleavy, MD, to Leadership Positions in Hematology

Kieron Dunleavy, MD, was appointed Director of Hematology at the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC. He is now also Chief of the Lymphoma Program at Georgetown University. Dr. Dunleavy joined Lombardi/Georgetown earlier this year. He is former Professor...

gastroesophageal cancer

FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma

On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. CheckMate 649 The...

Roswell Park Is First Site in Region Named a Resource for Patients With Rare Genetic Disease

Living with a genetic disorder that calls for regular monitoring, appropriate treatment, and emotional support calls for a multidisciplinary team that works together to coordinate patient care. Those diagnosed with von Hippel-Lindau (VHL) disease have a resource for complete and coordinated care in ...

AACR Inaugurates New Leadership at Virtual AACR Annual Business Meeting 2021

The American Association for Cancer Research (AACR) welcomed David A. Tuveson, MD, PhD, FAACR, as President of the organization for 2021–2022. He was inaugurated during the AACR Annual Business Meeting, held virtually on April 12. Dr. Tuveson is Director of the Cold Spring Harbor Laboratory Cancer...

City of Hope Renames Research Center as the Arthur Riggs Diabetes & Metabolism Research Institute

City of Hope has announced the renaming of its diabetes research center as the Arthur Riggs Diabetes & Metabolism Research Institute, in honor of its long-time director and research pioneer. Arthur Riggs, PhD, is known for scientific achievements that include developing the technology leading...

Dana-Farber Cancer Institute Opens New State-of-the-Art Location

Dana-Farber Cancer Instituterecently announced a major expansion with the opening of a hospital facility in Chestnut Hill, Massachusetts, to provide increased cancer care and outpatient services for adult patients in the region. The new 140,000–square foot, state-of-art outpatient facility is...

‘MethylationToActivity’: A Deep Learning Framework for Epigenetic Research

Scientists at St. Jude Children’s Research Hospital are using a type of machine learning to put a new twist on an established technique. The researchers created MethylationToActivity (M2A), a framework for using DNA methylation data to reveal promoter activity and gene expression. The results were...

UCLA Team Receives $6 Million From NIH to Explore New Pancreatic Cancer Therapies

A team of researchers from the University of California at Los Angeles (UCLA) Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health (NIH) to identify new ways to treat pancreatic cancer. “Pancreatic cancer is one of the ...

New Director of Neuro-Oncology Named to Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey has appointed Michael E. Salacz, MD, as Director of its Neuro-Oncology Program. The Associate Professor of Medicine at Rutgers Robert Wood Johnson Medical School joins Rutgers Cancer Institute from the University of Kansas Medical Center, where he served as...

Frederick W. Alt, PhD, Honored With 2021 AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) is recognizing geneticist Frederick W. Alt, PhD, with the 18th AACR Award for Lifetime Achievement in Cancer Research. Dr. Alt is a Howard Hughes Medical Institute investigator, Director of the Program in Cellular and Molecular Medicine at Boston ...

Maryam Lustberg, MD, MPH, Accepts Leadership Roles at Smilow Cancer Hospital, Yale Cancer Center

Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from...

Chênevert Family Brain Tumor Center Launched at Yale

Yale School of Medicine recently announced a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Center will be a leading institution in worldwide neuro-oncology research, bringing groundbreaking solutions and hope to patients with brain tumors. The gift will...

breast cancer
issues in oncology

John Marshall, MD, and Liza Marshall: When Cancer Strikes an Oncologist’s Family

John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a breast cancer survivor, talk about the impact of her diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their memoir has an important message.

kidney cancer
issues in oncology

Study Explores Racial Disparities in Renal Cell Carcinoma by Stage and Mortality

Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...

covid-19

Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden

Loneliness and social isolation have been significant problems for the general population during the COVID-19 pandemic, but for patients with cancer, these issues were particularly acute, likely due to isolation and social distancing, according to a recent study published by Miaskowski et al in the ...

prostate cancer
issues in oncology

Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race

A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...

solid tumors
issues in oncology

AI System May Aid in Diagnosing Cancer of Unknown Primary

In 1% to 2% of cancer cases, the primary site of tumor origin cannot be determined. Because many modern cancer therapeutics target primary tumors, the prognosis for a cancer of unknown primary (CUP) is poor, with a median overall survival of 2.7 to 16 months. In order to receive a more specific...

Advertisement

Advertisement



Advertisement